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Here, we synthesized novel chelation-free Zn(II)-complexes (1-3) [ZnCl2L2] of monodentate ligands with  
L = 2-isopropylimidazole (L1), 2-methylbenzimidazole (L2), and 2-methylbenzoxazole (L3) and evaluated their 
antibacterial, antioxidant and DNA binding activities. The chelation-free properties of these coordination complexes were 
confirmed by UV-visible spectroscopy, 1H NMR spectroscopy, single X-ray crystallography and elemental analysis. 
Complexes 1-3 exhibited substantial antibacterial activity against all antibiotic susceptible bacteria within a concentration 
range of 100-200 µg/ml while free ligands L1 and L2 exhibited weak antibacterial activity considerably concentration above 
200 µg/ml. Also, both complexes 2 and 3 were twice more active against methicillin-resistant Staphylococcus aureus 
(MRSA) than complex 1. Furthermore, we found that complexes 1-3 showed DNA binding activity with E. coli plasmid 
DNA and calf thymus DNA, which may be a plausible mechanism for their antibacterial activity. We also investigated the 
antioxidant activity of complexes 1-3 and found that complex 2 exhibited potential antioxidant activity compared to 
complexes 1 and 3. All these results suggest that the chelation-free Zn(II)-complexes can be the future candidates for more 
advance biological studies.  
Keywords: Zn(II) complex, 2-isopropylimidazole, 2-methylbenzimidazole, 2-methylbenzoxazole, DNA binding 
The continued development of antibiotic-resistant 
bacteria, as well as a shortage of new antibiotics in the 
pharmaceutical pipeline, is one of the serious threats 
to human health in the 21
st
 century
1
. Recently, 
methicillin-resistant Staphylococcus aureus (MRSA)
2
, 
an antibiotic-resistant bacteria, gives a challenge for 
the development of efficient antibacterial agents. 
MRSA can cause serious health problems like skin and 
soft tissue infections, necrotizing pneumonia, and 
death
3
. In addition to most beta-lactams antibiotics  
such as cloxacillin, MRSA also developed a  
resistance to erythromycin, clindamycin, aminoglycosides, 
fluoroquinolones, rifampicin, and cotrimoxazole
4
. 
These situations have revealed a substantial medical 
need to develop new antibiotics with minimal cross-
resistance. 
The monodentate azole derivatives are present in 
important biological compounds such as deoxyribonucleic 
acid, hemoglobin, histidine, Vitamin B12, and 
histamine
5
. Also, the azole nucleus is a crucial building 
block in fungicidal drug discovery such as ketoconazole, 
itraconazole, and fluconazole
6
. Most of the research 
showed that imidazole derivatives have several medicinal 
properties, such as antibacterial, anti-inflammatory  
and analgesic, antidepressant, antitubercular, anticancer, 
antileishmanial, and antiviral
7
. Lately, imidazole and 
imidazolium derivatives have been the subject of a 
thorough study of the antibacterial activity for their 
potential as promising therapeutic agents
8,9
. Moreover, 
the coordination of azole with metal ions enhances the 
biological activity of azoles, which is a consequence of 
the formation of metal complexes that assist the 
transport of azole into cells
10,11
. 
Zn(II) ion is one of the most commonly used 
antibacterial metal ion and is known to have less 
cytotoxicity towards mammalian cells
12
. Antibacterial 
activity of Zn(II) ions is similar to commercially used 
antibacterial metal ions such as Ag(I) and Cu(II) 
ions
13
. For many years Zn(II) ions have been added 
into many dental materials such as mouth rinses and 
toothpaste due to the ability of Zn(II) ion to inhibit the 
growth of albicans an oral cariogenic bacterium such 
INDIAN J CHEM, SEC A, MAY 2020 
 
 
590 
as Streptococcus mutans, Actinomyces viscosus, 
Lactobacillus casei, Staphylococcus aureus and 
Candidaalbicans
14,15
. 
Many chelated Zn(II)-azole complexes have been 
reported for their antibacterial activity against 
antibiotic-resistant bacteria such as MRSA
16,17
. However, 
no studies have been reported for the antibacterial 
activity of chelation-free Zn(II)-azole complexes. The 
carboxypeptidase-A that hydrolyzes the first peptide 
or amide bond of proteins is a nice example of 
chelation-free Zn(II)-histidine complex, which also 
reveals the bio-compatibility of such chelation-free 
Zn(II)-azole complexes
18
. Due to the bio-compatibility 
of Zn(II)-azole moieties, synthetic Zn(II)-azole 
complexes can easily be absorbed in the human body 
without any harmful effects
19
.  
The plausible mechanism of action of coordination 
complexes for antibacterial activity may be the 
inhibition of translation or transcription or both 
processes cause by binding of coordination complexes 
to DNA
20
. Thus, DNA binding assay of synthesized 
Zn(II)-complexes was performed against plasmid 
DNA (pDNA) and calf thymus DNA (CT-DNA). 
Additionally, the antioxidant activity of synthesized 
Zn(II)-complexes was performed as most of the 
Zn(II)-complexes show good antioxidant activities
21
. 
All these findings promote us to design and 
synthesize simple, cost-effective, and chelation-free 
azole complexes of Zn(II) metal ion and to  
compare their antibacterial activity with chelated  
Zn(II)-complexes.  
 
Materials and Methods 
All chemicals used in this research were purchased 
from Sigma-Aldrich and used without further 
purification, those include metal precursor Zn(II) 
chloride, ligands such as 2-isopropylimidazole,  
2-methyl benzimidazole and 2-methyl-benzoxazole, and 
the experimental solvents dichloromethane (DCM), 
acetonitrile, diethyl ether, n-hexane, methanol, dimethyl 
sulfoxide (DMSO) and dimethylformamide. 
 
Experimental Section 
 
Synthesis of dichlorobis(2-isopropylimidazole)Zinc(II) complex(1) 
ZnCl2 (5.0 mmol) and 2-isopropylimidazole  
(10 mmol) were added into two separate clean and  
dry 100 mL Erlenmeyer flask. Above solids were 
dissolved with stirring in approximately 20 mL of 
DCM solvent at room temperature. After complete 
dissolution, the 2-isopropylimidazole solution was 
added dropwise into the ZnCl2 suspension. The 
outcome was stirred for 15 min at room temperature 
until most of the ligands reacted with ZnCl2 to give 
white crystals (Scheme 1). White crystals were 
filtered using a glass funnel-filter setup. The solvent 
was removed over a rotary evaporator and kept for 
drying. Dried crystals were washed three times with 
hexane, filtered, and recrystallized with acetonitrile at 
room temperature. Then, the crystals were 
characterized by UV-visible analysis, 
1
H NMR, and 
single-X-ray analysis for molecular structure 
determination. Yield: 72%. Anal. Calcd. for 
C12H20N4Cl2Zn (356.61); C, 40.42; H, 5.65; N, 15.71; 
Cl, 19.88; Zn, 18.34. Found: C, 40.63; H, 5.44; N, 
15.82; Cl, 19.76; Zn, 18.56%.
1
H NMR (1) δ 1.24  
(6H, d, J = 6.7 Hz), 3.01 (1H, sept, J= 6.7 Hz), 7.16 
(1H, d, J= 3.3 Hz), 7.24 (1H, d, J= 3.3 Hz). UV-visible 
(DMSO) λmax, nm (log ε, L mol
−1
 cm
−1
): 287 (2.53). 
 
Synthesis of dichlorobis(2-methylbenzimidazole)zinc(II) complex 
(2) and dichlorobis(2-methylbenzoxazole)zinc(II) complex (3) 
A similar procedure was followed, as above, for the 
synthesis complexes 2 and 3 (Scheme 1). 
Complex 2: Yield: 85%. Anal. Calcd. For 
C32H3Cl2N8Zn (664.94); C, 57.8; H, 4.85; N, 16.85; 
Cl, 10.66; Zn, 9.83. Found C, 57.56; H, 4.68; N, 
16.58; Cl, 10.48; Zn, 9.62%. 
1
H NMR (2): 2.06  
(3H, s), 7.20–7.15 (4H, ddd), 7.63 (1H, s). UV-visible 
(DMSO) λmax, nm (log ε, L mol
−1 
cm
−1
): 288 (2.49). 
Complex 3: Yield: 64%. Anal. Calcd. For 
C16H14Cl2N2O2Zn (402.59); C, 47.73; H, 3.5; N, 6.96; 
O, 7.95; Cl, 17.61; Zn, 16.24. Found C, 47.83; H, 
7.72; N, 6.78; O, 9.68; Cl, 17.55; Zn, 16.29%. 
1
H NMR (3): 2.07–2.04 (3H, s), 7.58–7.42  
(2H, 7.32(ddd, J = 8.0, 7.8, 1.6 Hz), 7.37(ddd, J = 8.1, 7.8, 
1.8 Hz)), 7.73–7.68 (1H, ddd, J = 8.1, 1.6, 0.5 Hz), 
8.23–8.15 (1H, ddd, J = 8.0, 1.8, 0.5 Hz). UV-visible 
(DMSO) λmax, nm (log ε, L mol
−1
 cm
−1
): 289 (2.71). 
 
 
Scheme 1 — Synthesis of Zn(II)-complex (1-3). 
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X-ray structural determination 
The single X-ray structure analysis data were 
collected using a Bruker SMART Apex II X-ray 
diffractometer, and the structure, solution, and 
refinement was performed by using the SHELXS 
program. 
 
Antibacterial assay 
Minimum inhibitory concentration is the ending 
drug concentration that completely inhibits the visible 
growth of the microorganism in the micro dilution 
wells. The antibacterial activity of complexes 1-3, 
ligands L1 and L2, and streptomycin (positive control) 
were evaluated by the minimal inhibitory 
concentrations (MIC) assay. The test compounds were 
diluted with a twofold serial dilution method under 
standard conditions
22
. Antibacterial activity was 
performed against Gram-positive bacteria methicillin-
resistant Staphylococcus aureus (MRSA), Staphylococcus 
aureus, Bacillus subtilis, and Enterococcus faecalis) 
and Gram-negative bacteria (Escherichia coli, 
Klebsiella pneumonia, and Salmonella typhimurium). 
A single colony of each bacterium was inoculated in  
3 mL Luria broth and incubated for 18 h at 37 °C. 
Complexes 1-3, ligands L1 and L2, and streptomycin 
were dissolved in DMSO. The obtained solution was 
diluted with sterilize distilled water to give a final 
concentration of the test in 1% DMSO. Each well was 
dispensed with 100 µL aliquots of this solution and  
100 µL of bacteria inoculums into micro dilution 
sterileplates (SPL Life Sciences). The final test 
concentration of bacteria was approximately  
2 × 10
5
 CFU mL
–1
. The final concentration of complexes 
1-3, ligands L1 and L2, and streptomycin were ranged 
from 1.562 to 200 µg/mL all in twofold dilution steps. 
Each plate also contained one DMSO control  
(1% DMSO + bacteria), eight untreated negative 
controls (1% DMSO + complexes or ligands), and 
water control (dH2O + bacteria) to check the effect of 
1% DMSO on bacterial growth. These plates were 
incubated at 37 °C for 18 h. The optical density (OD) 
of the plates was recorded using a VersaMax 
Microplate Reader at 650 nm. The minimum inhibitory 
concentration (MIC) of the complexes 1-3, and ligands 
L1 and L2 were calculated by subtracting OD of 
negative control from OD of the sample.  
 
DNA mobility shift assays of plasmid DNA 
Plasmid DNA was isolated from 5 ml (OD = 1) 
transformed E. coli PET25b by using the DNA spin 
Plasmid DNA purification kit (INTRON 
Biotechnology). The concentration of purified DNA 
was approximately 40 μg/ 50 μL (according to the 
information in the catalogue).16 μg (20 μL) of pDNA 
was incubated at 25  C with 1 mM of the zinc 
complexes 1-3. The loading buffer, consisting of 
0.25% bromophenol blue, 0.25% xylene cyanol FF, 
and 30% (v/v) glycerol in water, was added after  
60 min to stop the reaction. The resulting mixture of 
pDNA and complexes were separated by electrophoresis 
on agarose gels (0.8% w/v), which contained 1 μg/mL 
ethidium bromide (EB) in 22.25 mM Tris, pH 8, 
22.25 mM Boric acid, 0.5 mM EDTA, at low voltage. 
DNA mobility shift assays were performed in a 
horizontal gel apparatus (Mupid-2plus Submarine 
electrophoresis system) for about 2.5 h. The gels were 
visualized in the presence of UV light. 
 
DNA mobility shift assays of calf thymus DNA 
0.08 mM CT-DNA was incubated at 25 °C with  
1 mM of zinc complexes 1-3. At 25 °C, the reaction 
was terminated after 30 min by the addition of loading 
buffer consisting of 0.25% bromophenol blue, 0.25% 
xylene cyanol FF, and 30% (v/v) glycerol in water. 
The resulting mixture of pDNA and complexes  
were separated by electrophoresis on agarose gels  
(1% w/v), which contained 1 μg/mL ethidium 
bromide (EB) in 22.25 mM Tris, pH 8, 22.25 mM 
Boric acid, 0.5 mM EDTA, at low voltage. DNA 
mobility shift assays were performed in a horizontal 
gel apparatus (Mupid-2plus Submarine electrophoresis 
system) for about 1 h. The gels were visualized in the 
presence of UV light. 
 
DPPH radical scavenging assay 
DPPH radical scavenging assay was performed 
with some modification as reported in the literature
23
. 
We prepared the solution of DPPH in methanol 
having absorbance of 0.416 at the wavelength of  
517 nm. The solutions of different concentrations  
(25 µg/ml to 400 µg/ml) of complexes 1-3 and rutin 
had been prepared in N,N-Dimethylformamide, and 
used for the assay. 1 ml solution of complexes 1-3 and 
rutin was mixed with 1ml of DPPH solution and 
incubated in dark for at least 5 h. The absorbance of  
1 mL solution of all incubated mixtures was measured 
at 517 nm after 5 h. DPPH radical scavenging activity 
was calculated for the different concentrations of 
complexes using the formula as given below. 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝐷𝑃𝑃𝐻 𝑟𝑎𝑑𝑖𝑐𝑎𝑙 
= [(𝐴𝑏𝑟 − 𝐴𝑎𝑟 )/𝐴𝑏𝑟 ] × 100  …(1) 
 
Where, Abr is the absorbance before reaction and Aar 
is the absorbance after the reaction. 
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Results and Discussion 
A series of chelation-free Zn(II)-complexes 1-3  
of formula [ZnCl2L2] (L= 2-isopropylimidazole (L1),  
2-methylbenzimidazole (L2), and 2-methylbenzoxazole 
(L3)) were synthesized with a typical synthesis 
procedure as reported earlier by us. Complexes 1-3 
were characterized by UV-visible spectroscopy,  
1
H NMR spectroscopy, single X-ray crystallography, 
and elemental analysis. The remarkable solubility of 
complexes 1-3 in the mixture of DMSO-water is a 
critical first step for possible applications of these 
complexes in biological systems. 
Synthesis of complexes 1-3 was a simple, single-
step, and cheap as these reactions were completed in 
one step within 15 min at room temperature compared 
to the synthesis of Schiff base and chelated azole 
Zn(II)-complexes which demand the multi-step 
synthesis of ligands at high temperature
24,25
. Similarly, 
the ligands used in complexes 1-3 are commercially 
available monodentate ligands compared to multi-step 
synthesized Schiff base ligands used in previous 
studies
26,27
. 
 
Molecular structures of Zn(II)-complexes 1-3 
The single X-ray crystal structures of complexes  
1-3 are shown in Figs. 1-3, respectively. The 
crystallographic data and refinement parameters of 
complexes 1-3 are summarized in Table 1. The 
coordination geometry around the Zn(II)-complexes 
1-3 is distorted tetrahedral similar to analogous 
Co(II)-complexes previously reported Tarte et al.
28
. 
Table 2 lists the pertinent bond distances and angles 
of complexes 1-3. Table 3 lists the hydrogen bonding 
in complex 1 and 2. The crystal structures of 
complexes 1-3 are orthorhombic, monoclinic, and 
triclinic, respectively. Complex 1 shows inter-
molecular hydrogen bonding between amine 
hydrogen of one of the 2-isopropylimidazole of the 
first complex and with chlorine atom of another 
complex N(2)-H(2A)...Cl(1). The crystal structure of 
complex 1 has extra stability in solid-state because of 
hydrogen bonding. Complex 2 shows three inter-
molecular H-bonding, one of which is between amine 
hydrogen of one of benzimidazole of the first 
complex molecule and nitrogen atom of neighboring 
benzimidazole ligand N(2)-H(2A)...N(5) and vice 
versa. The second H-bonding is between the amine 
hydrogen of benzimidazole ligand and one of the 
 
 
Fig. 1 ― Single X-ray crystal structure of dichlorobis(2-
isopropylimidazole)Zn(II)complex (1). 
 
 
Fig. 2 ― Single X-ray crystal structure of dichlorobis(2-
methylbenzimidazole)Zn(II) complex (2). 
 
 
 
Fig. 3 ― Single X-ray crystal structure of dichlorobis(2-
methylbenzoxazole)Zn(II) complex (3). 
NANDANWAR et al.: SYNTHESIS AND CHARCTERIZATION OF Zn(II)-AZOLE COMPLEXES 
 
 
593 
chlorine atoms of first complex N(6)-H(6A)...Cl(1), 
while third H-bonding is between the iminium 
hydrogen of the benzimidazole ligand and chlorine 
atom of first complex [N(7)-H(7A)...Cl(2)#2].  
In complex 2, each complex molecule is bonded with 
two neighboring benzimidazole ligands via inter-
molecular H-bonding, giving high stability to the 
crystal structure in solid-state. Complex 3 does not 
show any hydrogen bond in the crystal due to the 
absence of an amine N-H group in it.  
Furthermore, the N-Zn-N bond angle in complexes 
1, 2 and 3 are 115.91º, 104.95º, and 98.61º, 
respectively. The Cl-Zn-Cl bond angle of complexes 
1, 2, and 3 are 109.74º, 108.35º, and 114.19º, 
respectively. The reason for the higher N-Zn-N bond 
angle in complex 1 compared to complexes 2 and 3 
may be the steric hindrance between two imidazole 
ligands due to the repulsion between two bulkier 
isopropyl substituents. The moderate N-Zn-N bond 
angle in complex 2 compared to complex 1 and 3 may 
be due to intermolecular hydrogen bonding with 
benzimidazole ligands. The bond angle between  
Cl-Zn-Cl in complexes 1 and 2 is less compared to 
complex 3, which may result from steric hindrance 
Table ― 1 Crystallographic data and structure refinement for complexes 1–3 
Complexes 1 2 3 
Empirical formula C6 H10 Cl N2 Zn0.50 C32 H32 Cl2 N8 Zn C16 H14 Cl2 N2 O2 Zn 
Formula weight 178.29 664.93 402.56 
Temperature 298(1) K 296(2) K 296(1) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system Orthorhombic Monoclinic Triclinic 
Space group Pbcn P2(1)/n P-1 
Unit cell dimension 
a = 11.1941(2) Å, α = 90° 
b = 11.3578(2) Å, β = 90° 
c = 13.0719(3) Å, γ = 90°. 
a = 9.6964(2) Å, α = 90°. 
b = 22.0789(4) Å, β = 97.5710(10) ° 
c = 15.4249(3) Å, γ = 90° 
a = 6.6357(2) Å, α = 85.5930(10) ° 
b = 10.3514(2) Å, β = 79.4650(10) ° 
c = 12.9200(3) Å, γ = 73.9100(10) ° 
Volume 1661.97(6) Å3 3273.46(11) Å3 838.00(4) Å3 
Z 8 4 2 
Density (calculated) 1.425 mg/m3 1.349 mg/m3 1.595 mg/m3 
Absorption coefficient 1.792 mm-1 0.948 mm-1 1.793 mm-1 
F(000) 736 1376 408 
Crystal size 0.22 x 0.16 x 0.12 mm3 0.25 x 0.20 x 0.10 mm3 0.38 x 0.38 x 0.20 mm3 
Theta range for data collection 2.99 to 30.12° 1.84 to 28.28° 1.60 to 28.29° 
Index ranges 0<=h<=15, 0<=k<=16, 0<=l<=18 -12<=h<=12, 0<=k<=29, 0<=l<=20 -8<=h<=8, -13<=k<=13, 0<=l<=17 
Reflections collected 2423 8094 4132 
Independent reflections 2423 [R(int) = 0.0000] 8094 [R(int) = 0.0000] 4132 [R(int) = 0.0000] 
Completeness to theta = 28.28° 98.8 % 99.8 % 99.3 % 
Absorption correction Multi-scan Multi-scan Multi-scan 
Max. and min. transmission 0.8137 and 0.6939 0.9111 and 0.7974 0.7156 and 0.5490 
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 Full-matrix least-squares on F2 
Data / restraints / parameters 2423 / 0 / 87 8094 / 0 / 388 4132 / 0 / 211 
Goodness-of-fit on F2 1.042 1.034 1.081 
Final R indices [I>2sigma(I)] R1 = 0.0365, wR2 = 0.0970 R1 = 0.0463, wR2 = 0.1207 R1 = 0.0283, wR2 = 0.0754 
R indices (all data) R1 = 0.0567, wR2 = 0.1074 R1 = 0.0694, wR2 = 0.1351 R1 = 0.0314, wR2 = 0.0794 
Largest diff. peak and hole 0.834 and -0.249 e.Å -3 0.740 and -0.293 e.Å -3 0.368 and -0.404 e.Å-3 
 
Table ―2 Comparison of selected bond lengths (A˚) and angles (°) for complexes 1–3 
Complex 1 Complex 2 Complex 3 
Zn(1)-N(1) - 1.9980(16) Zn(1)-N(1) - 2.0176(18) Zn(1)-N(2) - 2.0642(15) 
Zn(1)-N(1)#1 - 1.9980(16) Zn(1)-N(3) - 2.0283(18) Zn(1)-N(1) - 2.0646(16) 
Zn(1)-Cl(1) - 2.2598(5) Zn(1)-Cl(1) - 2.2480(7) Zn(1)-Cl(2) - 2.2147(5) 
Zn(1)-Cl(1)#1 - 2.2599(5) Zn(1)-Cl(2) - 2.2721(7) Zn(1)-Cl(1) - 2.2282(5) 
N(1)-Zn(1)-N(1)#1 - 115.91(9) N(1)-Zn(1)-N(3) - 104.95(8) N(2)-Zn(1)-N(1) - 98.61(6) 
N(1)-Zn(1)-Cl(1) - 109.50(5) N(1)-Zn(1)-Cl(1) - 109.47(6) N(2)-Zn(1)-Cl(2) - 115.56(5) 
N(1)#1-Zn(1)-Cl(1) - 106.07(4) N(3)-Zn(1)-Cl(1) - 113.79(5) N(1)-Zn(1)-Cl(2) - 109.93(5) 
N(1)-Zn(1)-Cl(1)#1 - 106.07(4) N(1)-Zn(1)-Cl(2) - 112.56(6) N(2)-Zn(1)-Cl(1) - 105.81(4) 
N(1)#1-Zn(1)-Cl(1)#1 - 109.50(5) N(3)-Zn(1)-Cl(2) - 107.77(6) N(1)-Zn(1)-Cl(1) - 111.69(5) 
Cl(1)-Zn(1)-Cl(1)#1 - 109.74(3) Cl(1)-Zn(1)-Cl(2) - 108.35(3) Cl(2)-Zn(1)-Cl(1) - 114.19(2) 
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between their respective ligands (2-isopropylimidazole 
and 2-methylbenzimidazole), while complex 3  
does not have a steric hindrance between  
2-methylbenzoxazole. Both Zn-N bond lengths in 
complex 1 [1.9980 A˚] are symmetric, while that of 
complexes 2 [2.0176(18) A˚ and 2.0283(18) A˚], and 
3 [2.0642(15) A˚ and 2.0646(16) A˚] are more 
asymmetric. The density of the complexes 1, 2 and 3 
are 1.425 mg/m
3
, 1.349 mg/m
3
 and 1.595 mg/m
3
, 
respectively. The space group of the complexes1, 2 
and 3 are Pbcn, P2(1)/n, and P-1, respectively. These 
results indicate that complexes 1, 2 and 3 have 
different nucleation mechanisms. 
 
Antibacterial activity 
The in vitro antibacterial activity of complexes 1-3 
and ligands L1 and L2 were examined against Gram-
positive strains (methicillin-resistant Staphylococcus 
aureus (MRSA), Staphylococcus aureus, Bacillus 
subtilis, and Enterococcus faecalis) and Gram-negative 
strains (Escherichia coli, Salmonella typhimurium, and 
Klebsiella pneumoniae) with streptomycin as a positive 
control. Their MIC values were ranged between 1.56 to 
200 µg/mL using a two-fold serial dilution method. 
Positive control displayed significant antibacterial 
activity against all strains of tested bacteria except 
MRSA, whereas negative control and solvent control 
displayed no observable antibacterial activity against 
any of the test organisms, as shown in Table 4. 
Complexes 1 and 2 were twice more potent against  
S. aureus, and S. typhimurium with a MIC value of  
100 µg/mL compared to complex 3 with MIC value of 
200 µg/mL. Complexes 2 and 3 were twice more 
potent against B. subtilis with a MIC value of  
100 µg/mL compared to complex 1 with a MIC value 
of 200 µg/mL. Complexes 1 and 3 were twice more 
potent against E. faecalis with a MIC value of  
100 µg/mL compared to complex 2 with a MIC value 
of 200 µg/mL. Complex 1 was twice more potent 
against K. pneumoniae with a MIC value of 100 µg/mL 
compared to complexes 2 and 3 with a MIC value of 
200 µg/mL. Complexes 1-3 displayed similar 
antibacterial activity against E. coli with a MIC value 
of 100 µg/mL. Complexes 2 and 3 displayed excellent 
antibacterial activity against MRSA with a MIC value 
of 50 µg/mL, which was twice more compared to 
complex 1 with a MIC value of 100 µg/mL.  
All these results showed that complexes 1-3 displayed 
non-selective antibacterial activity against tested 
bacterial strain. There was a substantial increase in 
antibacterial activity of free ligands L1 and L2 against 
tested bacterial strain on coordination with Zn(II) ion
29
. 
Complexes 1-3 showed very high antibacterial activity 
compared to reported zinc complex and other metal 
complexes against antibiotic susceptible bacteria
30,31
. 
Complexes 1-3 displayed more antibacterial activity 
compare to chelated Zn(II)-benzimidazole complex 
against MRSA
32
. Complexes 1-3 were found to be 2.5 to 
5-foldmore activity against MRSA compared to 
macrocyclic Zn(II) Schiff base complex
26
. Zn(II)-
complexes of Schiff base ligands did not display 
antibacterial activity against MRSA
27,33
. 
Table ― 3 Hydrogen bond lengths (Å) and angles (°) for complexes 1 and 2 
Complex D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
1
a
 N(2)-H(2A)...Cl(1)#2 0.86 2.51 3.357(19) 166.6 
 
2
b
 
N(2)-H(2A)...N(5) 0.86 2.01 2.826(3) 157.7 
N(4)-H(4A)...N(8)#1 0.86 1.98 2.810(3) 161.5 
N(6)-H(6A)...Cl(1)#2 0.86 2.55 3.366(2) 159.2 
N(7)-H(7A)...Cl(2)#2 0.86 2.40 3.251(2) 170.3 
 
Symmetry transformations used to generate equivalent atoms:  
a = #1 -x, y, -z+1/2 #2 -x+1/2, y-1/2, z  
b = #1 x-1, y, z #2 -x+1/2, y+1/2, -z+3/2 
 
Table ― 4 MIC values of complexes 1–3 and ligands L1 and L2 in µg/mL 
Gram 
positive 
Bacteria 1 2 3 L1 L2 Streptomycin 
MRSA 100 50 50 > 200 > 200 > 200 
S. aureus 100 100 200 > 200 > 200 1.526 
B. subtilis 200 100 100 > 200 > 200 3.052 
E. faecalis 200 100 200 > 200 > 200 3.052 
Gram 
negative 
E. coli 100 100 100 > 200 >200 1.526 
S. typhimurium 100 100 200 > 200 > 200 6.104 
K. pneumoniae 100 200 200 > 200 > 200 3.052 
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Delocalization of π‐electrons over the whole 
complex ring may increase the lipophilicity of the 
complex compared with the free ligands, which 
enhance the penetration of the complex into the lipid 
membranes of the microorganisms
34
. Furthermore, the 
plausible mechanism of action for antibacterial 
activity of complexes 1-3 may be the inhibition of 
translation or transcription or both processes caused 
by binding of complexes 1-3 to DNA
20,35
.  
 
DNA mobility shift assay 
DNA multiplication is one of the pivotal events 
during cell division, and it is one of the key targets for 
antibacterial activity
20
. It is well-known that most of 
the metal complexes form strong interaction with 
DNA
36
. Thus, DNA mobility shift assays were carried 
out to investigate the ability of complexes 1-3 to 
interact with pDNA and CT-DNA. 
 
DNA mobility shift assays of plasmid DNA 
An initial amount of pDNA was incubated with 
complexes 1-3 (1mM). In DNA mobility shift assays, 
untreated supercoiled pDNA shows a relatively fast 
migration compared to treated supercoiled pDNA. 
However, if binding occurs between complexes and 
pDNA, the supercoil pDNA will relax to generate a 
slower-moving relax form
37
.The breakdown of a 
single strand of pDNA may lead to the occurrence of 
a DNA smear upon gel electrophoresis
38
. 
Fig. 4 shows the gel electrophoretic mobility shift 
of pDNA before (Lane 1) and after (Lane 2-4) 
incubation with complexes 1-3. pDNA is the mixture 
of the supercoiled form (upper band) and circular 
form (lower band). Complexes 1 and 2 led to the 
formation of a DNA smear, indicating extensive 
breaking of DNA strand, resulting in DNA degradation. 
Complex 3 interacts with pDNA which leads to the 
formation of the wide intense band in the upper band. 
 
DNA mobility shift assays of calf thymus DNA 
An initial amount of CT-DNA was incubated 1mM 
concentrations of the complexes 1-3. When CT-DNA 
was subject to the DNA mobility shift assays, relatively 
fast migration was observed for the untreated CT-DNA. 
However, if binding occurs between complexes and  
CT-DNA, the latter get relaxed to generate a slower-
moving relax form. The precession of the electrophoretic 
mobility is associated with the degradation of the  
CT-DNA
35
.  
Fig. 5 shows the gel electrophoretic mobility shift of 
CT-DNA before (lane 1) and after (lane 2-4) incubation 
with complexes 1-3. Complexes 1-3 shifted the mobility 
of CT-DNA substantially, which indicated the strong 
interaction of complexes 1-3 with CT-DNA.  
Complex 3 showed strong interaction with CT-DNA as 
compared to complexes 1 and 2. DNA mobility shift 
assays revealed that complexes 1 and 2 lead to the 
cleavage of pDNA and shift the mobility of CT-DNA. 
These results indicate that bacterial DNA cleavage is a 
plausible mechanism of action for the antibacterial 
activity of complexes 1 and 2. Complex 3 does not 
cleave pDNA but form strong interaction with pDNA 
and CT-DNA. Complex 3 may have different 
mechanisms of action compared to complexes 1 and 2. 
 
Antioxidant activity 
The aim of this experiment is to determine the 
radical scavenging activity of complexes 1-3 by the 
DPPH method in comparison to rutin
39
. 
 
 
Fig. 4 ― Agarose gel electrophoresis pattern of pDNA in the 
presence of complexes 1–3. Lane 1, DNA control; lane 2, DNA + 
1 (1 mM); lane 3, DNA + 2 (1mM); lane 4, DNA + 3 (1 mM). 
 
 
Fig. 5 ― Agarose gel electrophoresis pattern of CTDNA in the 
presence of the synthesized zinc complexes 1-3. Lane 1, CTDNA 
control; lane 2, DNA + 1 (1 mM); lane 3, DNA + 2 (1 mM); lane 
4, DNA + 3 (1 mM). 
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1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging 
activity 
DPPH is a stable free radical having strong purple 
color in methanol. It easily reacts with hydrogen atom 
donor moiety and electron donor moiety, which leads 
to a decrease in color intensity of DPPH to give a 
final reduced product with yellow color. To determine 
the antioxidant activity of desired compounds, this is 
the simple and best technique. Complex 2 showed 
higher radical scavenging activity compared to 
complexes 1 and 3, and rutin. The decreasing order of 
radical scavenging activity of complexes 1-3 and  
rutin is as follows: 2 > R > 3 > 1 (Fig. 6). The 
plausible mechanism of action for antioxidant activity 
of complexes 1-3 may be the abstraction of hydrogen 
free radical of amine or methyl group
40
. Under the 
influence of resonance and inductive effects, 
abstraction of hydrogen atom may occur easily. The 
molecules get stabilized due to resonance and 
inductive effects, which may facilitate the release of 
hydrogen atom
41
. 
 
Conclusions 
Three novel chelation-free Zn(II)-complexes (1-3) 
[ZnCl2L2] were synthesized and structurally 
characterized. Based on UV-visible spectroscopy, 
1
H 
NMR spectroscopy, single X-ray crystallography, and 
elemental analysis, the chelation-free property of 
pseudo-tetrahedral Zn(II)-complexes (1-3) were 
confirmed. Complexes 1-3 exhibited the nonselective 
antibacterial activity against all tested bacterial 
strains. Complexes 2 and 3 exhibited the highest 
antibacterial activity against MRSA with a MIC value 
of 50 µg/mL. pDNA mobility shift assay suggests that 
complexes 1 and 2 lead to the degradation of pDNA, 
while complex 3 efficiently shifts the mobility of 
pDNA. CT-DNA mobility shift assays suggest all the 
complexes bind to CT-DNA. Additionally, Zn(II)-
complexes (1-3) also displayed good antioxidant 
activity. Therefore, the information obtained from the 
present work suggests that the chelation-free Zn(II)-
complexes (1-3) can be the future candidates for more 
advance biological studies. 
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